Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet.
Glucocorticoid hormones are critical to respond and adapt to stress. Genetic variations in the glucocorticoid receptor (GR) gene alter hypothalamic-pituitary-adrenal (HPA) axis activity and associate with hypertension and susceptibility to metabolic disease. Here we test the hypothesis that reduced GR density alters blood pressure and glucose and lipid homeostasis and limits adaption to obesogenic diet. Heterozygous GR(betageo/+) mice were generated from embryonic stem (ES) cells with a gene trap integration of a beta-galactosidase-neomycin phosphotransferase (betageo) cassette into the GR gene creating a transcriptionally inactive GR fusion protein. Although GR(betageo/+) mice have 50% less functional GR, they have normal lipid and glucose homeostasis due to compensatory HPA axis activation but are hypertensive due to activation of the renin-angiotensin-aldosterone system (RAAS). When challenged with a high-fat diet, weight gain, adiposity, and glucose intolerance were similarly increased in control and GR(betageo/+) mice, suggesting preserved control of intermediary metabolism and energy balance. However, whereas a high-fat diet caused HPA activation and increased blood pressure in control mice, these adaptions were attenuated or abolished in GR(betageo/+) mice. Thus, reduced GR density balanced by HPA activation leaves glucocorticoid functions unaffected but mineralocorticoid functions increased, causing hypertension. Importantly, reduced GR limits HPA and blood pressure adaptions to obesogenic diet.
Michailidou
Z
Z
Endocrinology Unit, Centre for Cardiovascular Sciences, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.
Carter
R N
RN
Marshall
E
E
Sutherland
H G
HG
Brownstein
D G
DG
Owen
E
E
Cockett
K
K
Kelly
V
V
Ramage
L
L
Al-Dujaili
E A S
EA
Ross
M
M
Maraki
I
I
Newton
K
K
Holmes
M C
MC
Seckl
J R
JR
Morton
N M
NM
Kenyon
C J
CJ
Chapman
K E
KE
D050154:Adiposity / Q000187:drug effects / Q000235:genetics; D000450:Aldosterone / Q000378:metabolism; D000809:Angiotensins / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D002460:Cell Line; D004032:Diet / Q000009:adverse effects*; D004041:Dietary Fats / Q000009:adverse effects* / Q000494:pharmacology; D018149:Glucose Intolerance / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism*; D050356:Lipid Metabolism / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D010913:Pituitary-Adrenal System / Q000378:metabolism*; D011965:Receptors, Glucocorticoid / Q000235:genetics / Q000378:metabolism*; D012083:Renin / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics
D000809:Angiotensins; D001786:Blood Glucose; D004041:Dietary Fats; D011965:Receptors, Glucocorticoid; D000450:Aldosterone; D012083:Renin